['rheumatoid arthritis']
['upadacitinib', 'placebo']

        Inclusion Criteria:

          -  Diagnosis of rheumatoid arthritis (RA) for≥ 3 months.

          -  Treated for ≥ 3 months with ≥ 1 bDMARD therapy, but continue to exhibit active RA or
             had to discontinue due to intolerability or toxicity, irrespective of treatment
             duration prior to the first dose of study drug.

          -  Participant has been receiving csDMARD therapy ≥ 3 months and on a stable dose for ≥ 4
             weeks prior to the first dose of study drug. The following csDMARDs are allowed:
             methotrexate (MTX), sulfasalazine, hydroxychloroquine, chloroquine, and leflunomide. A
             combination of up to two background csDMARDs is allowed except the combination of MTX
             and leflunomide.

          -  Meets both of the following criteria:

          -  ≥ 6 swollen joints (based on 66 joint counts) and ≥ 6 tender joints (based on 68 joint
             counts) at Screening and Baseline Visits.

          -  hsCRP ≥ 3mg/L at Screening Visit.

        Exclusion Criteria:

          -  Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to
             tofacitinib, baricitinib, and filgotinib).

          -  History of any arthritis with onset prior to age 17 years or current diagnosis of
             inflammatory joint disease other than RA (including but not limited to gout, systemic
             lupus erythematosus, psoriatic arthritis, axial spondyloarthritis including ankylosing
             spondylitis and non-radiographic axial spondyloarthritis, reactive arthritis, overlap
             connective tissue diseases, scleroderma, polymyositis, dermatomyositis, fibromyalgia
             [currently with active symptoms]). Current diagnosis of secondary Sjogren's Syndrome
             is permitted.
      